Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation
British Journal of Pharmacology · 2024-12 · 181 (24) · 4939-4957
DOI: 10.1111/bph.16470 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2024-06-15. Written by Alisha Niskala and 4 co-authors. Institution: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Major MEDLINE topics: NLR Family, Pyrin Domain-Containing 3 Protein, Atrial Fibrillation, Inflammasomes, Signal Transduction. Cited 24 times so far (Crossref); 112 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Inflammatory signalling via the nod‐like receptor (NLR) family pyrin domain‐containing protein‐3 (NLRP3) inflammasome has recently been implicated in the pathophysiology of atrial fibrillation (AF). However, the precise role of the NLRP3 inflammasome in various cardiac cell types is poorly understood. Targeting components or products of the inflammasome and preventing their proinflammatory consequences may constitute novel therapeutic treatment strategies for AF. In this review, we summarise the current understanding of the role of the inflammasome in AF pathogenesis. We first review the NLRP3 inflammasome pathway and inflammatory signalling in cardiomyocytes, (myo)fibroblasts and immune cells, such as neutrophils, macrophages and monocytes. Because numerous compounds targeting NLRP3 signalling are currently in preclinical development, or undergoing clinical evaluation for other indications than AF, we subsequently review known therapeutics, such as colchicine and canakinumab, targeting the NLRP3 inflammasome and evaluate their potential for treating AF.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands.
- Gottfried Schatz Research Center, Division of Medical Physics & Biophysics, Medical University of Graz, Graz, Austria.
- Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany.
- Medicine and Research Center, Montréal Heart Institute and University de Montréal, Montréal, Canada.
- Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas, USA.
ORCID profiles: Arnela Saljic
Cite
APA
Niskala, A., Heijman, J., Dobrev, D., Jespersen, T., & Saljic, A. (2024). Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. British Journal of Pharmacology, 181(24), 4939-4957. https://doi.org/10.1111/bph.16470
Vancouver
Niskala A, Heijman J, Dobrev D, Jespersen T, Saljic A. Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation. British Journal of Pharmacology. 2024;181(24):4939-4957. doi:10.1111/bph.16470
BibTeX
@article{Niskala2024,
author = {Niskala, Alisha and Heijman, Jordi and Dobrev, Dobromir and Jespersen, Thomas and Saljic, Arnela},
title = {Targeting the NLRP3 inflammasome signalling for the management of atrial fibrillation},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {24},
pages = {4939--4957},
doi = {10.1111/bph.16470}
}
EUVIMED